Copyright: Clinics Cardive Publishing (Pty) Ltd. publisher
of Cardiovascular Journal of Africa.
Abstract
Objective:
Apical thrombus (AT) is a severe complication in myocardial infarction (MI), increasing the risk of thromboembolic events. Platelet-to-haemoglobin ratio (PHR) is a novel, inexpensive predictor of cardiovascular outcomes. This study explores the association between PHR and AT in MI patients.
Materials & methods: This retrospective study included 690 anterior MI patients (314 patients with AT and 376 patients without AT as a control group). Blood samples were analysed to calculate PHR, and echocardiographic evaluations identified AT. Logistic regression and ROC analysis determined independent predictors and the optimal PHR cut-off value for AT.
Results: PHRwas significantly higher in theAT group (2.03± 0.64 vs. 1.85±0.50; p<0.001). Multivariate analysis identified PHR, proximal LAD lesions, and lower LVEF as independent predictors. The PHR cut-off of 1.88 showed 69.3% sensitivity and 68.4% specificity.
Conclusion: PHR is a simple, accessible marker for predicting AT inMI patients. Its use may improve early risk stratification and clinical outcomes.
Materials & methods: This retrospective study included 690 anterior MI patients (314 patients with AT and 376 patients without AT as a control group). Blood samples were analysed to calculate PHR, and echocardiographic evaluations identified AT. Logistic regression and ROC analysis determined independent predictors and the optimal PHR cut-off value for AT.
Results: PHRwas significantly higher in theAT group (2.03± 0.64 vs. 1.85±0.50; p<0.001). Multivariate analysis identified PHR, proximal LAD lesions, and lower LVEF as independent predictors. The PHR cut-off of 1.88 showed 69.3% sensitivity and 68.4% specificity.
Conclusion: PHR is a simple, accessible marker for predicting AT inMI patients. Its use may improve early risk stratification and clinical outcomes.
Keywords:
apical thrombus, myocardial infarction, platelet-tohaemoglobin ratio
Submitted: May 18, 2024;
Accepted: December 9, 2024;
Published: June 30, 2025
Cardiovasc J Afr 2025; 36: 191-195
Volume 36, Issue 2
Cardiovasc J Afr 2025; 36: 191-195
Volume 36, Issue 2
DOI Citation Reference: dx.doi.org/10.5830/CVJA-2025-021

